{"entity":{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","aka":[],"tldr":"Relay Therapeutics uses computer simulations of how proteins move to design precise cancer pills. Its lead drug, zovegalisib, targets a mutated growth protein called PI3K-alpha in breast cancer while sparing the normal version.","summary":"Relay Therapeutics is a Cambridge, Massachusetts precision medicine company that combines computational modelling of protein motion with experimental chemistry. Its lead programme, zovegalisib (RLY-2608), is a mutant-selective, allosteric PI3K-alpha inhibitor that the company lists in phase 3 for PIK3CA-mutant breast cancer and in a phase 1/2 trial for vascular anomalies. RLY-8161, an NRAS inhibitor, is in a phase 1/2 trial in NRAS-mutant melanoma and other NRAS-mutant solid tumours. Lirafugratinib (RLY-4008), an FGFR2-selective inhibitor developed in FGFR2-fusion cholangiocarcinoma, was out-licensed to Elevar Therapeutics in December 2024. A non-oncology alpha-galactosidase A programme for Fabry disease is also listed. Relay completed its Nasdaq IPO in July 2020, selling 20 million shares at 20 US dollars per share according to its final prospectus.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://relaytx.com/"},{"label":"Pipeline","url":"https://relaytx.com/pipeline/"},{"label":"IPO prospectus (SEC 424B4)","url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm"}],"tags":[],"related":[],"cancers":["breast-hr-positive","melanoma","cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","ai-drug-design"],"targets":["pik3ca","fgfr2"],"drugs":["zovegalisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["IPO gross proceeds computed from the prospectus (20 million shares at 20 US dollars); final amount including the option was not confirmed. Founding year not sourced. The ai-drug-design tag reflects the company's computational platform as described on its site."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://relaytx.com/","ticker":"RLAY","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":400000000,"source":"https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm","note":"Final prospectus: 20 million shares at 20 US dollars per share, before the underwriters' option of up to 3 million additional shares"}]},"route":"/companies/relay-therapeutics/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/"}],"company":[{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/"}],"trial":[{"id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/"}]}}